Kayla Bigelow

Supplemental Figure 1 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Anthony R. Mato, Lindsey Elizabeth Roeker, Ryan Jacobs, Brian Thomas Hill et autres

Supplemental Figure 1: Overall survival of entire cohort from initiation of venetoclax.

Data from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Anthony R. Mato, Lindsey Elizabeth Roeker, Ryan Jacobs, Brian Thomas Hill et autres

AbstractPurpose: Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood. Experimental Design: To address this, we conducted a large international study to identify a cohort of 326 …

Data from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Anthony R. Mato, Lindsey Elizabeth Roeker, Ryan Jacobs, Brian Thomas Hill et autres

AbstractPurpose: Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood. Experimental Design: To address this, we conducted a large international study to identify a cohort of 326 …

Supplemental Figure 2 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Anthony R. Mato, Lindsey Elizabeth Roeker, Ryan Jacobs, Brian Thomas Hill et autres

Supplemental Figure 2: Progression free survival of patients without prior BTKi exposure who had progressed on venetoclax and were then treated with BTKi.

Supplemental Figure 1 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Anthony R. Mato, Lindsey Elizabeth Roeker, Ryan Jacobs, Brian Thomas Hill et autres

Supplemental Figure 1: Overall survival of entire cohort from initiation of venetoclax.

Supplemental Figure 2 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Anthony R. Mato, Lindsey Elizabeth Roeker, Ryan Jacobs, Brian Thomas Hill et autres

Supplemental Figure 2: Progression free survival of patients without prior BTKi exposure who had progressed on venetoclax and were then treated with BTKi.

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Anthony R. Mato, Lindsey Elizabeth Roeker, Ryan W. Jacobs, Brian Thomas Hill et autres

Abstract Purpose: Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood. Experimental Design: To address this, we conducted a large international study to identify a cohort of …

us, br, gb (code pays fourni par la source)

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Anthony R. Mato, Lindsey Elizabeth Roeker, Toby Andrew Eyre, Ryan W. Jacobs et autres

Introduction: Venetoclax (VEN) based therapy has become a standard of care in front line and relapsed-refractory (R/R) CLL based on favorable efficacy and toxicity. Whereas prospective data regarding activity of therapies following ibrutinib (IBR) or idelalisib (IDE) are available in the settings …

us, gb, br (code pays fourni par la source)